Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Report on National Symposium on Exploring New Insights of Pharmacoeconomics and Outcome Research
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) - India, Andhra Pradesh Regional Chapter head office at Raghavendra Institute of Pharmaceutical Education and Research – RIPER, in association with Indian Pharmaceutical Association (IPA) Anantapuramu Branch and Rural Development Trust (RDT) Hospitals Bathalapalli, Anantapuramu, Andhra Pradesh organized an One day “National Symposium on Exploring New Insights of Pharmacoeconomics and Outcome Research” on 5 December 2015 at RDT hospitals.
- Read more about National Pharmacy Week Celebrations 2015 at RIPER
Indian Pharmaceutical Association (IPA) Anantapuramu Local Branch, with branch head office at Raghavendra Institute of Pharmaceutical Education and Research (RIPER), celebrated the National Pharmacy Week – 2015 from 1^st–3^rd December 2015.
- Read more about Key biological markers for psychotic disorders identified
A team of researchers led by the University of Georgia has identified several biological markers that make it possible to classify mental disorders with greater precision. The findings may lead to improved diagnostics and treatments for those suffering from mental illness.

[adsense:336x280:8701650588]
- Read more about Kids with common allergies at high heart disease risk
Children with allergic disease, particularly asthma and hay fever, have twice the rate of high blood pressure and high cholesterol, setting them on course for heart disease at early age, finds a new study.
- Read more about Women loathe preventive drugs for breast cancer
Five in six women with increased risk of breast cancer turn down drugs that are likely to prevent the disease, finds cancer research scientists in Britain.
- Read more about Researchers create World’s first ibuprofen patch
Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch delivering the drug directly through skin to exactly where it is needed at a consistent dose rate.
- Read more about USFDA Approve QuilliChew ER chewable tablets
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer now offers two different products for the treatment of ADHD in patients ages 6 years old and above – liquid Quillivant XR® (methylphenidate HCl) CII and new QuilliChew ER chewable tablets.
- Read more about Unichem Lab gets USFDA nod for hypertension drug
Unichem Laboratories has received final approval from the US health regulator to market generic Irbesartan tablets, used in treating hypertension, in the American market.
- Read more about Takeda presents data from phase 3 study for multiple myeloma drug
Takeda Pharmaceutical Company Limited announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO® (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. The TOURMALINE-MM1 trial is an international, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate once-weekly oral ixazomib plus lenalidomide and dexamethasone compared to placebo plus lenalidomide and dexamethasone.
- Read more about AstraZeneca and Voluntis to test companion mobile app in ovarian cancer studies with the US National Cancer Institute
AstraZeneca announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. Voluntis has developed the service in close clinical collaboration with AstraZeneca and the US National Cancer Institute (NCI). It is delivered through a smartphone app paired with a web portal to help clinicians and patients manage side effects of hypertension and diarrhoea sometimes associated with combination therapy with cediranib and olaparib. Such side effects are traditionally described to care teams through manual, time-consuming and non-digitised channels.